Join hands in clinical inspections to cope with the challenge of infection prevention and control

In order to further discuss the latest developments in the prevention and treatment of infectious diseases in China, the second Roche Infectious Diseases Summit Forum was successfully held recently
.

Professor Wei Lai, Beijing Tsinghua Chang Gung Memorial Hospital, Tsinghua University, Academician Zhuang Hui of Peking University Health Science Center, Professor Wang Ning of Chinese Center for Disease Control and Prevention, Professor Shen Ning of Peking University Third Hospital, Professor Lu Hongzhou of Shenzhen Third People's Hospital, Hebei Medical University Third Professor Nan Yuemin and other experts from the hospital attended the forum and conducted in-depth discussions on key topics in the prevention and treatment of infectious diseases such as viral hepatitis and AIDS prevention and control
.

Professor Wei Lai, from Beijing Tsinghua Chang Gung Memorial Hospital, Tsinghua University, said in his speech: “Infectious diseases are one of the most serious public relations and health problems facing the world.
Early diagnosis, early detection, and early treatment are to curb the occurrence of infectious diseases.
An important path for development requires close collaboration between clinical and laboratory disciplines, based on the status quo of the diagnosis and treatment of infectious diseases in China, and establishing a high-quality system that meets China's actual and health needs, disease diagnosis and treatment monitoring needs
.
I
believe that through everyone's cohesion The level of prevention and treatment of infectious diseases in China will continue to improve steadily
.

"Improving the diagnosis rate: the top priority in curbing viral hepatitis.
According to the data released by the World Health Organization (WHO), the number of deaths from viral hepatitis worldwide since 2006 On the rise, in 2016, the number of deaths from viral hepatitis each year has exceeded that of AIDS, tuberculosis and malaria; if no measures are taken, by 2040, the annual number of deaths from viral hepatitis will exceed the total number of deaths from AIDS, malaria, and tuberculosis[1] , The prospects for prevention and control are grim
.

At the 69th World Health Assembly, WHO formally proposed an international strategy for the eradication of viral hepatitis by 2030-reducing new viral hepatitis infections by 90% and reducing viral hepatitis-related deaths by 65%.
At the same time, it put forward 5 key points.
Intervention indicators: ①Inoculation rate of 3 shots of hepatitis B vaccine in newborns reached 90%; ②Inoculation rate of hepatitis B vaccine in time within 24 hours after birth of newborns reached 90%; ③Blood safety reached 100% and safe injection reached 100%; ④Reduce injecting drugs The harm brought by it reached 83%; ⑤The diagnosis rate of hepatitis B reached 90%, and the treatment rate reached 80%
.

Academician Zhuang Hui Peking University School of Medicine "In recent years, the number of reported cases of hepatitis B in China has generally shown a downward trend
.
The
WHO report in 2019 shows that there are about 1.
5 million new HBV infections worldwide each year, of which about 45,000 new cases in China, accounting for only 3% This proves that China has achieved great results in the prevention and vaccination of hepatitis B; but at the same time, it should be noted that there are 820,000 deaths from HBV infection in the world each year, and 300,000 deaths in China, accounting for a total of the global data.
36.
6%; According to the latest Polaris report released in 2020, the diagnosis rate of hepatitis B in China is 25%, and the treatment rate is 20%, which is higher than the 2016 level (diagnosis rate 19%, treatment rate 11%) [2], but the distance There is still a big gap in the WHO goals
.

" Academician Zhuang Hui pointed out, "As a major country of hepatitis B, the prevention and control work facing China is still very arduous.
We need more accurate detection methods, effective treatment methods and convenient medical service systems to continue to improve.
The diagnosis rate and treatment rate of hepatitis B ensure that hepatitis B patients can be effectively managed and treated in a timely manner, and we will go all out for the global realization of the goal of '2030 elimination of viral hepatitis'
.

"The increase in the diagnosis rate of viral hepatitis is inseparable from strong testing.
Technical support
.

Studies have shown that HBsAg quantitative detection has a high predictive value and is suitable as an indicator for early monitoring of treatment; serum HBV DNA detection can be used for diagnosis, assessment of virus replication status, decision whether to start antiviral therapy, and monitoring of antiviral therapy effect
.

Roche Diagnostics Elecsys® HBsAg using quantitative electrochemiluminescence, good specificity, sensitivity, quantitative detection of DNA binding cobas® TaqMan® HBV can help develop individualized clinical treatment plan and optimize the treatment of chronic hepatitis
.

Professor Nan Yuemin, Hebei Medical University Third Hospital, talked about the current status of hepatitis C treatment.
Professor Nan Yuemin said: “The global hepatitis C treatment has entered the era of cure.
Direct antiviral drugs (DAA) can cure more than 95% of HCV infections.
, Making the eradication of hepatitis C a reality
.

However, the main challenge for China to improve the cure rate of hepatitis C at this stage is also to increase the awareness and diagnosis rate of the disease
.

We are pleased to see that the rapid development of laboratory testing technology in recent years has provided hepatitis C diagnosis and clinical cure.
The monitoring and prevention of recurrence provide important support
.

"Generally speaking, serological testing for hepatitis C antibodies is the first step in screening for HCV infection.
If hepatitis C antibodies are positive, HCV RNA testing should be performed for qualitative confirmation
.

Roche Diagnostics Elecsys® anti-HCV II has excellent sensitivity and specificity, and realizes fully automatic detection.
The detection time is only 18 minutes.
It is an ideal choice for early screening of hepatitis C antibody.
Combined with cobas® TaqMan® HCV RNA detection, the lowest detection The lower limit reaches 15 IU/mL, and the sensitivity is high, which can accurately determine the virus response status and effectively improve the level of clinical diagnosis and treatment
.

Continuing struggle: We are still on the road to prevent HIV.
Humanity’s struggle against AIDS has lasted for 40 years.
With the continuous development of medicine and the continuous improvement of the prevention and treatment system, the current situation of the global AIDS epidemic has greatly improved: new global AIDS infections The number has shown a slow and continuous downward trend, and the AIDS mortality rate has continued to decline since 2005
.

In 2020, 27.
4 million of the 37.
6 million HIV-infected people worldwide are receiving treatment, while the number of people treated in 2010 was only 7.
8 million; in 2020, the number of new HIV infections dropped to 1.
5 million, which was the same as the 2.
1 million in 2010.
Compared with, achieved a 30% drop [3]
.

In order to further contain and prevent AIDS, the United Nations Programme issued a political declaration on ending the AIDS epidemic by 2030 in June this year, and put forward the "four 95%" target: that is, 95% of people at risk of HIV infection accept comprehensive preventive measures; 95 % Of HIV-infected people receive treatment; 95% of the treated patients have the virus suppressed and 95% of HIV-infected people know their infection status, and finally achieve the goal of ending the AIDS epidemic by 2030 [4]
.

Professor Wang Ning from the China Centers for Disease Control and Prevention Professor Wang Ning introduced the development status of China's AIDS prevention and control cause: "China's AIDS prevention work has achieved fruitful results in recent years: the coverage of testing has continued to expand, and the follow-up management of infected persons has been improved; According to the report data for 2020, the number of HIV/AIDS medical records reported in China has declined to a certain extent compared with that in 2019.
At the same time, with the popularization of blocking drugs in recent years and the increase in blocking awareness, the AIDS mortality rate has continued to decrease
.

However, it still needs to be recognized .
future prevention and control situation is still grim: there is a large difference in endemic areas, the number of the elderly population over 60 years of infection continues to rise and other complex features
.

"Professor Lu Hongzhou Shenzhen third people's hospital for the future focus of China's AIDS prevention work, Professor Lu Hongzhou stressed: "In recent years, there is a proportion of reported data that needs special attention, that is, the proportion of late AIDS cases in China is still high
.

Grasping the detection work and increasing the diagnosis rate of infected patients are the key'sentinel points' of China's current AIDS prevention work.
——Among the three 90% prevention and control targets proposed in China’s 13th Five-Year Plan of Action, the first 90% is “more than 90% of infected persons who have been diagnosed and know their own infection status”, and serology As a preliminary screening method for HIV infection, testing plays a vital role
.

"Improving the sensitivity and specificity of HIV laboratory testing is essential for timely detection of HIV-infected patients, as well as for early clinical treatment and management of the patient’s condition
.

Roche’s diagnosis Elecsys HIV Duo test uses the principle of the sandwich method and simultaneously detects HIV-1 through different reaction cups.
The p24 antigen and HIV-1 and HIV-2 antibodies are then used to automatically calculate the main results through the e-flow system unique to the cobas e 801 platform, and the secondary results (HIV antigens and antibodies) are used to assist in the selection of appropriate samples for confirmation.
The process has greatly improved the efficiency of HIV detection; at the same time, research reports show that the sensitivity of the kit to different HIV subtypes is 100%, the specificity of blood donor samples and diagnostic samples are as high as 99.
87% and 99.
92%, and the anti-interference ability Outstanding [5]
.

Professor Ning Shen and Professor Ning Shen from Peking University Third Hospital emphasized: “Early detection and early diagnosis and treatment are important consensuses for the prevention and control of infectious diseases.
It will become more stable.
Therefore, clinical and laboratory disciplines need to maintain close communication, strengthen mutual learning and collaboration, and form a joint force to promote the continuous improvement of the management level of infectious diseases in China
.

"Mr.
Yao Guoliang, General Manager of Roche Diagnostics China Mr.
Yao Guoliang, General Manager of Roche Diagnostics China, said: "The challenges brought by infectious diseases have never stopped
.

In the face of this disease problem, as a leader in the field of in vitro diagnostics, Roche Diagnostics has always been committed to supporting the continuous development of the level of diagnosis and treatment of infectious diseases in China with more cutting-edge and innovative diagnostic products
.

In the future, Roche Diagnostics will also continue to increase investment in this field, and work closely with experts in clinical and laboratory disciplines to continue to bring more high-medical value testing products and services to Chinese patients, in order to promote infectious diseases in China.
Contribute more to the diagnosis and treatment ability and realize the whole-process management of patient-centered infectious diseases
.

”[1]Thomas DL.
N Engl J Med, 2019, 380(21):2041-2050[2]https://cdafound.
org/dashboard/polaris/dashboard.
html[3]UNAIDS, June 2021[4] "United Nations Political Declaration on HIV/AIDS"[5] Mühlbacher A.
et al.
J Clin Virol.
2019 Mar;112:45-50.